Non‐Apoptotic Inhibition of Colorectal Cancer Proliferation by Sclareol via Ferroptosis Involving SLC7A11 / GPX4 Modulation
Phytotherapy Research · 2025
DOI: 10.1002/ptr.70010 ↗At a glance
Journal article in Phytotherapy Research, 2025. Written by Yu-Xi Li and 7 co-authors. Institution: Department of Traditional Chinese Medicine, Shanghai Jiao Tong University School of Medicine Affiliated Ruijin Hospital, Shanghai, China. Major MEDLINE topics: Ferroptosis, Colorectal Neoplasms, Phospholipid Hydroperoxide Glutathione Peroxidase, Amino Acid Transport System y+. Cited 4 times so far (Crossref); 63 references. Funded by: National Natural Science Foundation of China.
Abstract (original language)
Colorectal cancer (CRC) is a prevalent and lethal malignancy necessitating new treatments. Sclareol, the primary active component of Salvia sclarea L., exhibits diverse pharmacological properties, making it a promising anti‐cancer drug warranting further investigation. To evaluate Sclareol's action in CRC cell death, various methods were performed, including cell viability and colony formation assays, EdU assay, flow cytometry for cell cycle analysis and apoptosis, as well as TUNEL staining, transmission electron microscopy (TEM), reactive oxygen species (ROS) detection, and Fe 2+ fluorometric assay. RNA sequencing and pathway analysis, combined with in silico molecular docking, and immunoblotting, were conducted to determine the mechanism of action of Sclareol. A CRC xenograft model in immunocompetent mice was used to evaluate Sclareol's in vivo efficacy and toxicity, with immunohistochemistry confirming its mechanism of action. Sclareol significantly suppressed CRC cell proliferation and induced cell cycle arrest in vitro without significantly inducing apoptosis. Ferroptosis as a promising mechanism of action was validated through TEM, ROS detection, and Fe 2+ staining. RNA sequencing analysis revealed enrichment in metal ion‐transporter activity. Molecular docking analysis showed direct binding of Sclareol to the key ferroptosis‐related target solute carrier family 7 member 11 (SLC7A11). Additionally, Sclareol downregulated the expression of SLC7A11, nuclear factor erythroid 2‐related factor 2 (Nrf2), and glutathione peroxidase 4 (GPX4) proteins, indicating ferroptosis induction in vitro. Significant tumor growth inhibition was observed without hepatic or renal toxicities, with immunohistochemistry confirming the suppression of ferroptosis‐ and proliferation‐related markers in vivo. Sclareol inhibits CRC growth by modulating the ferroptosis pathway through the SLC7A11/GPX4 axis. Sclareol shows promise as a therapeutic agent in CRC, warranting further pre‐clinical studies to confirm its efficacy and safety.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Traditional Chinese Medicine, Shanghai Jiao Tong University School of Medicine Affiliated Ruijin Hospital, Shanghai, China.
- Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
ORCID profiles: Lan Zheng
Funding
- National Natural Science Foundation of China
Cite
APA
Li, Y. X., Wu, Y., Li, Q., Huang, Y. Q., Yuan, Y. Y., Su, Y. N., Cheng, C. S., & Zheng, L. (2025). Non‐Apoptotic Inhibition of Colorectal Cancer Proliferation by Sclareol via Ferroptosis Involving SLC7A11 / GPX4 Modulation. Phytotherapy Research. https://doi.org/10.1002/ptr.70010
Vancouver
Li YX, Wu Y, Li Q, Huang YQ, Yuan YY, Su YN, et al. Non‐Apoptotic Inhibition of Colorectal Cancer Proliferation by Sclareol via Ferroptosis Involving SLC7A11 / GPX4 Modulation. Phytotherapy Research. 2025. doi:10.1002/ptr.70010
BibTeX
@article{Li2025,
author = {Li, Yu-Xi and Wu, Yuan and Li, Qiong and Huang, Yu-Qing and Yuan, Ying-Ying and Su, Yan-Ni and Cheng, Chien-Shan and Zheng, Lan},
title = {Non‐Apoptotic Inhibition of Colorectal Cancer Proliferation by Sclareol via Ferroptosis Involving SLC7A11 / GPX4 Modulation},
journal = {Phytotherapy Research},
year = {2025},
doi = {10.1002/ptr.70010}
}
EUVIMED